Evidence map›Paper›PMID 35127501›Full record

ArticleFrontiers in oncology2021

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres

Xuhua Duan, Juanfang Liu, Xinwei Han, Jianzhuang Ren, Hao Li, Fengyao Li, Shuguang Ju

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. One-step fabrication of lidocaine/CalliSpheresJournal of translational medicine · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xuhua DuanDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Juanfang LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinwei HanDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jianzhuang RenDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hao LiDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fengyao LiDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shuguang JuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCalliSpheres

methodsA total of 71 patients with huge HCC who underwent DEB-TACE or cTACE were consecutively enrolled in this retrospective cohort study. Treatment response was assessed at first month (M1), third month (M3), and sixth month (M6) after TACE therapy; progression-free survival (PFS) and overall survival (OS) were evaluated; liver function indexes were recorded before TACE operation (M0), at first week (W1), M1 and M6 after TACE therapy; adverse events which occurred after TACE operation were recorded.

resultsDEB-TACE presented with higher objective response rate (60.0% vs. 29.7%,

conclusionDEB-TACE with CSM presents with better treatment response, survival profiles, as well as safety profiles compared with cTACE in treatment for huge HCC patients.

Indexed as

DEB-TACEhuge HCCsafetysurvivaltreatment response

Identifiers

PMID35127501
PMCPMC8814413
OpenAlexW4207041860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.